Steven Cohen Seagen Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $9.58 Million - $10.8 Million	50,000 New	50,000 $10.6 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $29.7 Million - $47.2 Million	232,657 Added 120.24%	426,157 $86.3 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $14.2 Million - $16.9 Million	121,300 Added 168.01%	193,500 $24.9 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $106 Million - $141 Million	-785,622 Reduced 91.58%	72,200 $9.88 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $58.3 Million - $96 Million	-535,378 Reduced 38.43%	857,822 $152 Million

Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $90.7 Million - $120 Million	758,619 Added 119.55%	1,393,200 $201 Million
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $25.3 Million - $33.9 Million	-177,500 Reduced 21.86%	634,581 $98.1 Million
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $16.8 Million - $20 Million	-117,832 Reduced 12.67%	812,081 $138 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $29.1 Million - $34.7 Million	215,377 Added 30.14%	929,913 $147 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $98.3 Million - $136 Million	714,536 New	714,536 $99.2 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.